Quels sont les modèles économiques existants pour les solutions innovantes en faveur de la prévention santé ?
Dani joined +ND Capital in our Lausanne office in 2019. He is currently a board member of Cytoki, EVIR Therapeutics, Vandria, Osasuna Therapeutics and a board observer of Amazentis. He is also a former board member of Arctos Medical (sold to Novartis) and CellPoint (sold to Galapagos) .
Prior to this, Dani spent 12 years as a venture capital investor in the life sciences and 10 years in academic research. Dani’s motivation has been to translate scientific innovation into better healthcare. He is passionate about working with entrepreneurs to develop better medicines and cures. Prior to joining +ND Capital, Dani served on the board of 15 companies in Europe and the US, ranging from drug development to medical devices and digital health. Some of these companies have developed viruses capable of curing cancer, engineered proteins to tackle rare diseases and invented devices to keep heart failure patients safe. Dani became a venture capital investor at Index Ventures (Geneva), to join later Aravis Ventures (Zurich) and Imperial Innovations – IP Group (London). During his previous life as a scientist at the University of Geneva and at the Swiss Federal Institute of Technology (EPFL) in Lausanne, Dani conducted research in immunology and virology (HIV).
Dani holds a PhD in molecular biology from the University of Barcelona and an executive MBA from EOI Business School (Madrid).